Only 10% of men aged 45-69 years who progress from no or mild to moderate or severe lower urinary tract symptoms are treated, study finds.
Lack of efficacy is the main reason for the switch.
Compared with standing, sitting was associated with significantly lower post-void residual volume.
Following surgery, improvement in sexual satisfaction correlated with improvements in all lower urinary tract symptoms.
This rate of incidental PCa detection is lower than found in previous studies.
Researchers compared transurethral resection of the prostate with prostate artery embolization in a randomized trial.
Ejaculatory function worsens, however, in men taking 5 alpha-reductase inhibitors.
Using leave-one-out cross-validation, sensitivity of 78 percent and specificity of 67 percent.
Alpha blockers and 5-alpha reductase inhibitors increase the risk of ejaculatory dysfunction, a systematic review and meta-analysis shows.
New study also suggests that low preoperative hematocrit and albumin levels predict adverse outcomes.
Cumulative rates of clinical success were 87.2% at 3 months, 80.2% at 18 months, and 72.3% at 36 months (long term).
Older and obese men and those with low HDL cholesterol are more likely to have the syndrome as a determinant of prostatic enlargement.
Early results from a small group of patients show a clinical success rate of 95%.
The FDA has approved the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with BPH.
Improvements observed in urinary symptoms and bone mineral density.